TY - JOUR
T1 - Antioxidant supplementation has a positive effect on oxidative stress and hematological toxicity during oncology treatment in cervical cancer patients
AU - Fuchs-Tarlovsky, Vanessa
AU - Rivera, María Amanda Casillas
AU - Altamirano, Karolina Alvarez
AU - Lopez-Alvarenga, Juan Carlos
AU - Ceballos-Reyes, Guillermo Manuel
N1 - Funding Information:
Manuscript received July 22, 2002; revised January 3, 2003. This work was supported in part by the Deutsche Forschungsgemeinschaft (SFB-TR3 Mesial Temporal Lobe Epilepsies) under Project A2: Nonlinear analysis of electric potentials and magnetic fields in the epileptic brain. Asterisk indicates corresponding author. *C. Rieke is with the Department of Epileptology, University of Bonn, Sigmund Freud Str.25, 53105 and with the Helmholtz-Institute for Radiation and Nuclear Physics, University of Bonn, Nussallee 14-16, 53115 Bonn, Germany (e-mail: rieke@iskp.uni-bonn.de).
PY - 2013/5
Y1 - 2013/5
N2 - Background and aim: Hematological toxicity and oxidative stress are common in cancer patients. Antioxidant supplementation has been shown to decrease oxidative stress, but there is still controversy on this topic. The aim of this study was to determine the effect of antioxidant supplementation on oxidative stress, hematological toxicity, and quality of life (QoL) in cervical cancer patients. Methods: Randomized, single-blinded controlled trial in women with cervical cancer treated with radiotherapy and chemotherapy with cisplatin. Subjects were randomly assigned to receive antioxidant supplement or placebo supplement. Plasma concentrations of malondialdehyde, free carbonyls, and blood biometry were measured. EORTC quality of life questionnaire was applied before and after oncology treatment. Student's t test for independent samples and X2 for categorical variables were performed. Results: One hundred three patients were randomly assigned to receive treatment with antioxidants 49 (48 %) or placebo 54 (52.40 %). At the end of the oncology treatment, hemoglobin levels were maintained, and global QoL was better only in the supplemented group (p < 0.025). Conclusions: Antioxidant supplementation in patients treated with chemotherapy and radiotherapy apparently decreased oxidative stress, maintained hemoglobin levels, and improved QoL; however, more studies are needed to study the long-term effect of this intervention.
AB - Background and aim: Hematological toxicity and oxidative stress are common in cancer patients. Antioxidant supplementation has been shown to decrease oxidative stress, but there is still controversy on this topic. The aim of this study was to determine the effect of antioxidant supplementation on oxidative stress, hematological toxicity, and quality of life (QoL) in cervical cancer patients. Methods: Randomized, single-blinded controlled trial in women with cervical cancer treated with radiotherapy and chemotherapy with cisplatin. Subjects were randomly assigned to receive antioxidant supplement or placebo supplement. Plasma concentrations of malondialdehyde, free carbonyls, and blood biometry were measured. EORTC quality of life questionnaire was applied before and after oncology treatment. Student's t test for independent samples and X2 for categorical variables were performed. Results: One hundred three patients were randomly assigned to receive treatment with antioxidants 49 (48 %) or placebo 54 (52.40 %). At the end of the oncology treatment, hemoglobin levels were maintained, and global QoL was better only in the supplemented group (p < 0.025). Conclusions: Antioxidant supplementation in patients treated with chemotherapy and radiotherapy apparently decreased oxidative stress, maintained hemoglobin levels, and improved QoL; however, more studies are needed to study the long-term effect of this intervention.
KW - Antioxidant therapy
KW - Cervical cancer
KW - Hematological toxicity and quality of life (QoL)
KW - Oxidative stress
UR - http://www.scopus.com/inward/record.url?scp=84879692789&partnerID=8YFLogxK
U2 - 10.1007/s00520-012-1674-6
DO - 10.1007/s00520-012-1674-6
M3 - Artículo
C2 - 23238653
SN - 0941-4355
VL - 21
SP - 1359
EP - 1363
JO - Supportive Care in Cancer
JF - Supportive Care in Cancer
IS - 5
ER -